Optimised CRISPR/CAS9 Delivery for Disease Model Generation

摘要

Amsbio has launched DNA-ln~R CRISPR - an innovative transfection reagent that simplifies and accelerates genome editing using large plasmids and difficult-to-transfect cells for life science researchers generating disease models. Since its emergence, CRISPR-Cas9 technology has been rapidly adopted as a mainstream approach for performing genetic manipulation. This powerful tool has transformed the process of generating 'footprint-free' cellular models for studying genetic diseases. Using this approach, researchers can easily generate disease-relevant isogenic models to determine the impact of correcting or introducing disease-relevant mutations on cellular phenotypes in a tissue-appropriate context. However, problems have remained with certain cell types that are more resistant to transfection and for larger plasmids.